Stock Splits
By The Online Investor Staff, updated Fri., Sep. 30, 4:20 PM
| This Slide: #8 of 25 |
Slide #8. NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) — 1 for 30 Reverse Split
Announced:
9/12/2022
Stock Split:
1 for 30
Record Date:
9/12/2022
Pay Date:
9/13/2022
NRBO Optionable?:
Yes
NeuroBo Pharmaceuticals is a clinical-stage biotechnology company. ANA001, Co.'s drug candidate, is an oral niclosamide formulation and is being developed as a treatment for patients with moderate coronavirus disease (patients not requiring ventilators). Co.'s NB-01 addresses various mechanisms that contribute to neuropathic pain and nerve degeneration in diabetic and other peripheral neuropathies. Co.'s NB-02 is in development for the symptomatic and disease modifying treatment of neurodegenerative diseases, including Alzheimer's disease and tauopathies. Co.'s Gemcabene is an oral therapy designed to target known lipid metabolic pathways to lower levels of LDL-C, hsCRP and triglycerides. 
NRBO Detailed Information Page & Split History »
|
|||||||||||||||||||||
Open the NRBO Page at The Online Investor (in a new window) »
 Free NRBO Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
|
Strong Buy (4.00 out of 4) 80th percentile
(ranked higher than approx. 80% of all stocks covered)
Analysts' Target Price: NRBO Stock Forecast Based on Zacks ABR data; powered by Xignite |
